WuXi Biologics (Cayman) Inc.
2269
Classement en actions
#987
Headquartered in Wuxi, China, and established in 2014, WuXi Biologics (Cayman)... Headquartered in Wuxi, China, and established in 2014, WuXi Biologics (Cayman) Inc. delivers a comprehensive, integrated suite of services spanning the entire biologics lifecycle, from initial discovery through development to large-scale manufacturing. The company's operations have a global footprint, serving clients across the People's Republic of China, North America, Europe, and other international regions. Its diversified offerings also include specialized consultation in biopharmaceutical technology, international sales contracting, the development and deployment of advanced testing methodologies, and robust marketing and sales support. Furthermore, WuXi Biologics is involved in providing dedicated biologics clinical and manufacturing services, the production and distribution of various medical products, contract development and manufacturing (CDMO) for vaccines and associated businesses, and acting as a supplier of key materials. The firm maintains strategic partnerships with notable entities such as ImmuneOncia Therapeutics, Legochem Biosciences Inc., Worg Pharma, OncoC4, and Exelixis Inc.
Prix de l'action
$5.77
Capitalisation boursière
$23.74B
Changement (1 jour)
-8.38%
Changement (1 an)
25.13%
Pays
CN
Échange WuXi Biologics (Cayman) Inc. (2269)
Catégorie
Healthcare
Revenus pour WuXi Biologics (Cayman) Inc. (2269)
Revenus en Oct 2026 TTM : 0
Selon les derniers rapports financiers de WuXi Biologics (Cayman) Inc., le chiffre d'affaires actuel de l'entreprise (TTM) est de 0. En 2026, l'entreprise a réalisé un chiffre d'affaires de 0 égal à le chiffre d'affaires de l'année 2026, qui était de 0. Le chiffre d'affaires correspond au revenu total généré par la vente de biens ou de services. Contrairement au bénéfice, aucune dépense n'est déduite.
Historique des revenus pour WuXi Biologics (Cayman) Inc. de 2014 à 2026
Revenus à la fin de chaque année
| Année | Revenus | Changez |
|---|---|---|
| 2025 | $3.11B | 21.73% |
| 2024 | $2.56B | 6.32% |
| 2023 | $2.41B | 8.72% |
| 2022 | $2.21B | 36.72% |
| 2021 | $1.62B | 88.45% |
| 2020 | $859.12M | 50.17% |
| 2019 | $572.10M | 55.27% |
| 2018 | $368.45M | 48.08% |
| 2017 | $248.81M | 74.67% |
| 2016 | $142.45M | 66.06% |
| 2015 | $85.78M | 60.11% |
| 2014 | $53.58M | 0.00% |
Revenus d’entreprises similaires ou concurrentes
| Entreprise | Revenus | Différence de revenus | Pays |
|---|---|---|---|
| $12.62B | - |
US
|
|
| $2.23B | - |
US
|
|
| $15.74B | - |
AU
|
|
| $6.02B | - |
NL
|
|
| - | - |
CH
|
